Breaking News

CordenPharma Expands Early Clinical Peptide Manufacturing

GMP manufacturing area is designed to produce peptide APIs from gram to kilogram range for clinical phase 1 and 2 requirements.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CordenPharma is commissioning new GMP capacities at its Frankfurt site to manufacture early clinical phase peptide APIs for pharma and biotech customers. The investment is expected to be fully operational in 2Q24 and authorized by German authorities in 2H24. This follows an expansion of the Frankfurt site in 2020 for non-GMP manufacturing.   The Frankfurt site will add 1000 m2 of manufacturing space, including two fully equipped lines comprised of a Solid Phase Peptide Synthesizer (SPPS), High...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters